Search

Your search keyword '"Vicier, Cécile"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Vicier, Cécile" Remove constraint Author: "Vicier, Cécile"
38 results on '"Vicier, Cécile"'

Search Results

1. Pervasive chromosomal instability and karyotype order in tumour evolution

2. Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations

4. TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients

6. Response to systemic therapy in fumarate hydratase–deficient renal cell carcinoma

8. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial

12. PB1844: REAL: A RETROSPECTIVE STUDY OF THE CLINICO-BIOLOGICAL FEATURES OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES PATIENTS INCLUDED IN AN EARLY PHASE TRIAL AT A COMPREHENSIVE CANCER CENTER.

16. Whole exome sequencing of rare aggressive breast cancer histologies

18. Abstract CT188: ICT01, an anti-butyrophilin 3A targeted mAb activating g9d2 T cells, induces immune remodeling of the tumor microenvironment and clinical responses in combination with pembrolizumab in patients with advanced solid tumors who failed prior checkpoint inhibitor therapy: EVICTION Trial

19. Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial

20. Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study

21. Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study

22. 739P Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial

23. 503 Clinical activity of ICT01, an anti-BTN3A-targeted, γ9δ2-activating mAb, alone and in combination with pembrolizumab in patients with advanced/refractory solid tumors: EVICTION trial

24. Additional file 1 of Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial

25. Additional file 4 of Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial

26. Additional file 2 of Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial

31. Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors

34. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer

35. Pervasive chromosomal instability and karyotype order in tumour evolution

37. Elevated Serum Cytokines and Trichomonas vaginalisSerology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer

Catalog

Books, media, physical & digital resources